Global Top Three Trade Places As Going Gets Tough, Especially In The US
Mylan has moved up to become the world’s leading generics, biosimilars and OTC player, according to Generics Bulletin’s newly compiled global rankings. Sandoz has surpassed troubled Teva into second spot, but is set to surrender that position once it sells its US solid-dose and dermatology business to India’s Aurobindo, which has already moved into the global top 10.
You may also be interested in...
In an eventful year for the off-patent industry, the world’s leading generics and biosimilars players have switched places in Generics Bulletin’s newly-compiled global sales ranking.
As the US generics market continues to experience turbulence, the industry’s largest players are adopting a wide range of strategies to cope with the uncertainty as signs of stabilization begin to emerge.
Alembic is building up an extensive roster of solid-dose, ophthalmic and dermatological drugs to introduce in the US. With facility clearance from the FDA, the Indian firm can now target the US market for oral solids to treat cancer.